Europe PMC
metadata only
CC BY 4.0
A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Hypophosphatemia-factors associated with its development and 90-day mortality effect: a prospective observational study.#368112
- Effects of Pioglitazone in Congenital Adrenal Hyperplasia#802857
- The POWERED Study: Prophylaxis With Metformin to Prevent PTDM#876898
- Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer#869839
- Macrophage phenotype is determinant for fibrosis development in keloid disease#482509
Record · ID 485378
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive